Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-3.03 Insider Own0.30% Shs Outstand40.83M Perf Week-7.28%
Market Cap775.36M Forward P/E- EPS next Y-2.84 Insider Trans-85.88% Shs Float35.06M Perf Month-9.01%
Income-97.20M PEG- EPS next Q-0.61 Inst Own68.00% Short Float14.20% Perf Quarter3.66%
Sales6.10M P/S127.11 EPS this Y-47.00% Inst Trans0.09% Short Ratio5.08 Perf Half Y36.52%
Book/sh3.76 P/B5.05 EPS next Y-0.70% ROA-40.10% Target Price41.00 Perf Year-52.80%
Cash/sh4.54 P/C4.18 EPS next 5Y- ROE-56.10% 52W Range12.43 - 41.24 Perf YTD17.01%
Dividend- P/FCF- EPS past 5Y- ROI-54.10% 52W High-53.95% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low52.78% ATR1.30
Employees89 Current Ratio5.70 Sales Q/Q12.50% Oper. Margin- RSI (14)37.13 Volatility4.70% 5.92%
OptionableYes Debt/Eq0.34 EPS Q/Q-208.80% Profit Margin- Rel Volume0.40 Prev Close19.20
ShortableYes LT Debt/Eq0.26 EarningsMar 07 AMC Payout- Avg Volume979.85K Price18.99
Recom2.40 SMA20-8.43% SMA50-13.56% SMA2000.78% Volume395,243 Change-1.09%
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Apr-13-17 02:05PM  Editas foes add legal firepower as gene-editing case goes to appeal American City Business Journals
Mar-31-17 04:09PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal
Mar-30-17 07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy at bizjournals.com
07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy American City Business Journals
Mar-29-17 08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017 Capital Cube
08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017
Mar-28-17 06:04AM  Coverage initiated on Editas Medicine by Chardan Capital Markets +5.75%
Mar-22-17 10:30AM  Latest Editas research pact could be worth up to $1 billion at bizjournals.com
10:30AM  Latest Editas research pact could be worth up to $1 billion American City Business Journals
Mar-20-17 04:51PM  Editas Get A Vetr Upgrade To Strong Buy Benzinga
Mar-17-17 04:50PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme -10.48%
Mar-16-17 09:05PM  Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock GlobeNewswire
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage The Wall Street Journal
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage at The Wall Street Journal
12:50AM  Pig organs in humans? George Church-founded biotech banks $38M to try at bizjournals.com
12:50AM  Pig organs in humans? George Church-founded biotech banks $38M to try American City Business Journals
Mar-15-17 05:46PM  Allergan (AGN) and Editas Tie Up to Treat Eye Diseases Zacks -5.38%
04:14PM  Editas Medicine, Inc., Announces Proposed Offering of Common Stock GlobeNewswire
08:46AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-14-17 05:24PM  Here's Why Editas Medicine Gained as Much as 17.2% Today at Motley Fool
04:30PM  Allergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today
11:25AM  CRISPR Could Change The World, But Right Now $90 Million Is Enough at Forbes
11:15AM  Allergan, Editas In Gene-Editing Eye Disease Pact at Investopedia
09:59AM  Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases
09:26AM  Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira
09:00AM  Editas bags $90M in gene editing R&D pact with Allergan at bizjournals.com
08:35AM  Editas Medicine surges 8% on $90 million Allergan research and development deal at MarketWatch
08:22AM  Allergan signs deal with Editas for gene-editing-based eye treatments
08:00AM  Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases PR Newswire
Mar-09-17 01:04PM  EDITAS MEDICINE, INC. Financials +8.02%
10:41AM  Editas Medicine, Inc. :EDIT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
Mar-08-17 02:50PM  Intellia R&D head says new gene-editing data shows path to human trials at bizjournals.com
12:53AM  Edited Transcript of EDIT earnings conference call or presentation 7-Mar-17 10:00pm GMT
Mar-07-17 07:46PM  Editas reports 4Q loss
05:00PM  Editas Medicine Inc Earnings Call scheduled for 5:00 pm ET today
04:10PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update GlobeNewswire
07:07AM  Q4 2016 Editas Medicine Inc Earnings Release - After Market Close
Mar-06-17 01:00PM  New Cambridge-based, Third Rock-backed biotech revealed in federal filing at bizjournals.com
12:31PM  3 Stocks I'd Never Touch at Motley Fool
Mar-03-17 09:10AM  Editas Medicine COO to Leave Company -6.81%
09:07AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
09:00AM  Editas Medicine Announces Departure of Chief Operating Officer GlobeNewswire
Feb-28-17 04:01PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results GlobeNewswire +8.39%
08:00AM  Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017 GlobeNewswire
Feb-27-17 04:01PM  Editas Medicine to Present at Investor Conferences in March GlobeNewswire
Feb-21-17 05:00AM  How Much Is a CRISPR Patent License Worth? at Forbes
Feb-17-17 02:36PM  Court Rules Against Berkeley In CRISPR Patent Case at Investopedia +5.13%
Feb-16-17 05:45PM  Here's Why Editas Medicine Jumped 32.6% Higher Today at Motley Fool
01:34PM  Both sides claim victory angling for millions in potential royalties and licenses in gene-editing patent dispute at bizjournals.com
Feb-15-17 05:29PM  Gene editing patent ruling sways fortune of biotech hopefuls +28.84%
04:33PM  Why Fortress Investment Group, Editas Medicine, and Hertz Global Holdings Jumped Today at Motley Fool
03:52PM  Stop Freaking Out About CRISPR! (Except For One Thing) at Forbes
03:19PM  Editas Medicine's stock soars after favorable ruling in CRISPR patent dispute at MarketWatch
02:37PM  Broad Institute wins case over gene-editing patents, boosting Editas shares at bizjournals.com
01:58PM  Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference GlobeNewswire
Feb-14-17 11:00AM  Use Gene Tools for Disease, Not Designer Babies, Panel Says at Bloomberg
Feb-10-17 04:01PM  Editas Medicine to Present at Upcoming February Investor Conferences GlobeNewswire
Feb-07-17 06:21PM  Why Crisper Therapeutics Tumbled 12.4% in January at Motley Fool
Feb-01-17 05:00AM  How A 2015 Trial Sheds Light On The CRISPR Patent Case at Forbes
Jan-23-17 04:07PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Financial Statements and Exhibits
Jan-13-17 12:46PM  10 Most Interesting Companies In The World at Insider Monkey
Jan-10-17 03:33PM  Editas CEO: Our goal is to repair broken genes at the lev...
Jan-09-17 08:00AM  Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference GlobeNewswire +5.03%
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com -5.24%
08:18AM  Editas Medicine (EDIT) Shares March Higher, Can It Continue?
Jan-04-17 08:01AM  Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +8.57%
Dec-21-16 08:01AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
Dec-19-16 02:35PM  A better approach to gene editing? Editas snags new exclusive license from Broad at bizjournals.com
07:00AM  Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies GlobeNewswire
Dec-16-16 12:00PM  Gene-editing firms form patent alliance against Editas, Broad at bizjournals.com
Dec-15-16 12:20AM  A new name and new fund will ensure Cambridge's Flagship 'feels like a startup' at bizjournals.com
12:01AM  Flagship Ventures Evolves Name To Flagship Pioneering PR Newswire
Dec-09-16 06:36AM  Here is What Hedge Funds Think About Editas Medicine Inc (EDIT) at Insider Monkey
Dec-06-16 03:19PM  Is This Why CRISPR Therapeutics Stock Rallied 21.6% in November? at Motley Fool
Dec-01-16 10:59AM  ETFs with exposure to Editas Medicine, Inc. : December 1, 2016
Nov-30-16 07:34AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 30, 2016
Nov-23-16 01:10PM  Shares of Seattle, Waltham biotech Juno crash after patient deaths at bizjournals.com
11:00AM  Is Editas Medicine (EDIT) Stock a Solid Choice Right Now?
Nov-15-16 04:11PM  Chinese Pioneer First Human Gene Edit, Triggering Biotech Space Race (CRSP, EDIT) at Investopedia
Nov-14-16 05:41PM  [$$] Partners Innovation Fund Raises $39M at The Wall Street Journal
Nov-09-16 04:13PM  EDITAS MEDICINE, INC. Files SEC form 10-Q, Quarterly Report
08:00AM  Editas Medicine to Present at the Stifel Healthcare Conference 2016 GlobeNewswire
Nov-08-16 12:26AM  Edited Transcript of EDIT earnings conference call or presentation 7-Nov-16 10:00pm GMT
Nov-07-16 05:00PM  Editas Medicine Inc Earnings Call scheduled for 5:00 pm ET today
04:58PM  Editas reports 3Q loss
04:27PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Editas Medicine Announces Third Quarter 2016 Results and Update GlobeNewswire
07:07AM  Q3 2016 Editas Medicine Inc Earnings Release - Time Not Supplied
Nov-05-16 12:13PM  The Unsung Heroes of CAR-T at Motley Fool
Oct-31-16 04:01PM  Editas Medicine to Host Conference Call Discussing Third Quarter 2016 Corporate Update and Results GlobeNewswire +7.94%
Oct-25-16 08:46AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : October 25, 2016 -10.07%
Oct-20-16 01:37PM  5 Stocks Poised for Major Breakouts +5.68%
Oct-17-16 07:30AM  Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016 GlobeNewswire
Oct-16-16 07:00AM  Should You Buy Stock in the Biotech Discovery of the Century? at Motley Fool
Oct-07-16 06:58PM  [$$] Crispr Therapeutics Plans $75M IPO at The Wall Street Journal -6.33%
Oct-06-16 08:00AM  Editas Medicine Reports Inducement Grant to New Chief Medical Officer GlobeNewswire
Oct-05-16 02:35PM  4 breakout stocks to watch at MarketWatch
08:30AM  Editas Medicine (EDIT) Catches Eye: Stock Moves Up 11%
Oct-03-16 04:01PM  Editas Medicine to Present at the Jefferies Gene Editing/Therapy Summit GlobeNewswire
Developing gene editing therapies based on CRISPR/Cas9 technology.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glucksmann AlexandraChief Operating OfficerMar 15Option Exercise0.651,000650118,788Mar 17 11:53 AM
Glucksmann AlexandraChief Operating OfficerMar 15Sale26.411,00026,410117,788Mar 17 11:53 AM
Glucksmann AlexandraChief Operating OfficerFeb 15Option Exercise0.656,0003,900123,788Feb 16 06:39 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise3.233,0009,6903,000Feb 16 06:41 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale19.203,00057,6000Feb 16 06:41 PM
Glucksmann AlexandraChief Operating OfficerFeb 15Sale20.586,000123,484117,788Feb 16 06:39 PM
Hack Andrew A. F.Chief Financial OfficerJan 11Option Exercise3.2315,00048,45015,000Jan 13 04:41 PM
Hack Andrew A. F.Chief Financial OfficerJan 11Sale19.2015,000288,0000Jan 13 04:41 PM
Polaris Venture Management Co.10% OwnerDec 07Sale15.8275,0001,186,5003,797,144Dec 08 05:07 PM
Bitterman KevinDirectorDec 07Sale15.8275,0001,186,5003,797,144Dec 08 05:07 PM
Polaris Venture Management Co.10% OwnerDec 06Sale15.8750,000793,5003,872,144Dec 07 04:44 PM
Bitterman KevinDirectorDec 06Sale15.8750,000793,5003,872,144Dec 07 04:43 PM
Polaris Venture Management Co.10% OwnerDec 05Sale15.7480,0001,259,2003,922,144Dec 07 04:44 PM
Bitterman KevinDirectorDec 05Sale15.7480,0001,259,2003,922,144Dec 07 04:43 PM
Polaris Venture Management Co.10% OwnerNov 23Sale15.7121,480337,4514,002,144Nov 28 04:37 PM
Bitterman KevinDirectorNov 23Sale15.7121,480337,4514,002,144Nov 28 04:35 PM
Polaris Venture Management Co.10% OwnerNov 22Sale15.7712,819202,1564,023,624Nov 23 04:38 PM
Bitterman KevinDirectorNov 22Sale15.7712,819202,1564,023,624Nov 23 04:36 PM
Polaris Venture Management Co.10% OwnerNov 16Sale16.3030,830502,5294,036,443Nov 18 05:46 PM
Bitterman KevinDirectorNov 16Sale16.3030,830502,5294,036,443Nov 18 05:44 PM
Bitterman KevinDirectorNov 15Sale16.5730,865511,4284,067,273Nov 16 04:47 PM
Polaris Venture Management Co.10% OwnerNov 15Sale16.5730,865511,4284,067,273Nov 16 04:47 PM
Bitterman KevinDirectorNov 14Sale17.1658,035995,8814,098,138Nov 16 04:47 PM
Polaris Venture Management Co.10% OwnerNov 14Sale17.1658,035995,8814,098,138Nov 16 04:47 PM